An Intellia Therapeutics therapy that uses CRISPR to perform in vivo genomic edits has clinical data showing that the therapeutic effects continue for a year in patients. The biotech now plans to speak with regulators about the design for a pivotal clinical trial testing this therapy, a potential one-time treatment for a rare inherited disease.
Intellia Therapeutics, Inc. (NASDAQ:NASDAQ:NTLA) Q1 2022 Earnings Conference Call May 05, 2022, 08:00 ET Company Participants Ian Karp - SVP, IR & Corporate Communications John Leonard.
First gene-editing treatment injected into the blood reduces toxic protein for up to 1 year science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.